NOVARTIS ENTERS INTO PARTNERSHIP WITH INCYTE
MPNRF | August 30, 2007
Novartis will collaborate with Incyte on the further development of two of Incyte Corp.’s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis.
For more information: